Passage Bio, Inc.(PASG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PASG Passage Bio, Inc.

盘前交易 07-02 05:45:55 EDT

4.58

-0.30

-6.15%

盘前4.44

-0.14-3.06%

04:00 EDT

最高4.92	最低4.42	成交量5.86万
今开4.92	昨收4.88	日振幅10.25%
总市值1,469万	流通市值1,313万	总股本320.78万
成交额27.17万	换手率2.04%	流通股本286.72万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PASG","market":"US","secType":"STK","nameCN":"Passage Bio, Inc.","latestPrice":4.58,"timestamp":1782936000000,"preClose":4.88,"halted":0,"volume":58592,"hourTrading":{"tag":"盘前","latestPrice":4.44,"preClose":4.58,"latestTime":"04:00 EDT","volume":210,"amount":932.4000000000001,"timestamp":1782979216327,"change":-0.14,"changeRate":-0.030568,"amplitude":0},"delay":0,"changeRate":-0.06147540983606554,"floatShares":2867176,"shares":3207810,"eps":-11.84,"marketStatus":"盘前交易","change":-0.3,"latestTime":"07-02 05:45:55 EDT","open":4.92,"high":4.92,"low":4.42,"amount":271739.19045439997,"amplitude":0.102459,"askPrice":5.42,"askSize":100,"bidPrice":4.03,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.84,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782999000000},"marketStatusCode":1,"adr":0,"listingDate":1582866000000,"exchange":"NASDAQ","adjPreClose":4.58,"preHourTrading":{"tag":"盘前","latestPrice":4.44,"preClose":4.58,"latestTime":"04:00 EDT","volume":210,"amount":932.4000000000001,"timestamp":1782979216327,"change":-0.14,"changeRate":-0.030568,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.45,"preClose":4.58,"latestTime":"19:09 EDT","volume":1019,"amount":4530.5303,"timestamp":1782947381058,"change":-0.13,"changeRate":-0.028384,"amplitude":0.030568},"volumeRatio":0.12647150450244135,"impliedVol":1.9527,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/PASG/","defaultTab":"news","newsList":[{"id":"1144596174","title":"Passage Bio任命史密斯博士执掌合并后公司，马修·帕特森将担任董事长，彼得·科拉布奥诺加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1144596174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144596174?lang=zh_cn&edition=full","pubTime":"2026-06-25 04:06","pubTimestamp":1782331601,"startTime":"0","endTime":"0","summary":"Passage Bio公司宣布了其合并后领导层的重要人事安排。根据最新决定，史密斯博士将出任合并后公司的首席执行官，全面负责公司的战略规划与日常运营。与此同时，马修·帕特森被任命为董事会主席，他将主导董事会的各项工作。此外，彼得·科拉布奥诺也作为新成员加入公司董事会，预计将为公司治理带来新的视角与经验。这一系列高层变动旨在强化公司治理结构，并为未来的业务整合与发展奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108832601","title":"Passage Bio终止与Gemma Bio Therapeutics的研究、合作及许可协议 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1108832601","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108832601?lang=zh_cn&edition=full","pubTime":"2026-05-28 04:19","pubTimestamp":1779913171,"startTime":"0","endTime":"0","summary":"Passage Bio, Inc.已根据美国证监会提交的文件，正式终止了与Gemma Bio Therapeutics先前达成的研究、合作及许可协议。这一决定标志着双方在特定治疗领域的联合开发项目告一段落。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174838808","title":"Passage Bio公司：CDR 1级患者经PBFT02治疗12个月后全脑萎缩减少64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174838808","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174838808?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:04","pubTimestamp":1776683091,"startTime":"0","endTime":"0","summary":"Passage Bio公司宣布，其针对CDR 1级患者的研究数据显示，接受PBFT02治疗的病患在12个月后展现出显著疗效——全脑萎缩程度大幅降低64%。这一突破性进展为神经退行性疾病治疗领域带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106905680","title":"Passage Bio公司：Pbft02治疗组CDR 1患者在12个月时额颞叶皮层萎缩减少54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106905680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106905680?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:04","pubTimestamp":1776683054,"startTime":"0","endTime":"0","summary":"一项最新临床研究数据显示，接受Pbft02治疗的临床痴呆评级为1分的患者，在12个月疗程后额颞叶皮层萎缩程度显著降低54%。该结果凸显了Passage Bio公司研发的基因疗法在延缓神经退行性疾病进程方面的潜力。研究通过脑部影像学检测发现，治疗组患者大脑关键区域的退化速度明显减缓。这一发现为早期干预神经退行性疾病提供了新的临床证据。研究人员将继续追踪长期疗效，进一步评估该疗法对患者生活质量的改善作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162365385","title":"Passage Bio宣布聘请Wedbush Pacgrow担任财务顾问 启动战略替代方案评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1162365385","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162365385?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:03","pubTimestamp":1776683004,"startTime":"0","endTime":"0","summary":"基因疗法公司Passage Bio, Inc.近日披露两项重要决策：公司已正式聘请Wedbush Pacgrow作为其财务顾问，同时启动对战略替代方案的全面评估。此举标志着这家生物技术企业正积极寻求优化发展路径，旨在通过专业机构的协助探索包括潜在合作、资产重组或资本运作在内的多重战略可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PASG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122148136","title":"Passage Bio公司：Pbft02总体耐受性良好 未报告新的治疗相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1122148136","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122148136?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:03","pubTimestamp":1776682994,"startTime":"0","endTime":"0","summary":"Passage Bio公司宣布，其研发药物Pbft02在临床试验中展现出良好的安全性特征。最新数据显示，该治疗方案总体耐受性良好，且未出现任何新的与治疗相关的严重不良事件报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156154931","title":"Passage Bio公布Uplift-D试验最新中期数据 同步更新监管与企业进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1156154931","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156154931?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:01","pubTimestamp":1776682870,"startTime":"0","endTime":"0","summary":"Passage Bio, Inc.今日披露了其Uplift-D临床试验的最新中期分析结果，并就监管审批流程及公司运营动态向市场作出全面通报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192716609","title":"Passage Bio公司：推进亨廷顿病差异化临床前项目，预计2026年下半年选定临床候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1192716609","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192716609?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:11","pubTimestamp":1772539872,"startTime":"0","endTime":"0","summary":"Passage Bio公司正在积极推进其针对亨廷顿病的差异化临床前研发项目。该项目取得显著进展，公司预计将在2026年下半年完成临床候选药物的遴选工作。\n这一重要里程碑标志着公司在神经科学领域基因治疗研发方面迈出关键一步。候选药物的确定将为后续临床开发奠定坚实基础，有望为亨廷顿病患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609538871","title":"Passage Bio, Inc.盘中异动 早盘股价大跌5.39%报10.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609538871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609538871?lang=zh_cn&edition=full","pubTime":"2026-02-05 23:10","pubTimestamp":1770304232,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日23时10分，Passage Bio, Inc.股票出现波动，股价急速跳水5.39%。截至发稿，该股报10.00美元/股，成交量2.71万股，换手率0.85%，振幅5.11%。Passage Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Aim Immunotech Inc.、Liminatus Pharma, Inc.、Bone Biologics Corp C/Wts 13/10/2026 涨幅较大，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Propanc Biopharma, Inc.较为活跃，换手率分别为1647.83%、1065.08%、212.13%，振幅较大的相关个股有Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Liminatus Pharma, Inc.，振幅分别为51.18%、31.47%、30.07%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205231033a480c8ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205231033a480c8ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603362726","title":"Passage Bio, Inc.盘中异动 早盘股价大跌7.48%报16.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603362726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603362726?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:02","pubTimestamp":1768316532,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日23时02分，Passage Bio, Inc.股票出现异动，股价快速跳水7.48%。截至发稿，该股报16.57美元/股，成交量5090股，换手率0.16%，振幅5.47%。Passage Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Decoy Therapeutics Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Briacell Therapeutics Corp.涨幅较大，Decoy Therapeutics Inc.、Scisparc Ltd.、Briacell Therapeutics Corp.较为活跃，换手率分别为1155.04%、1131.37%、288.57%，振幅较大的相关个股有Decoy Therapeutics Inc.、Briacell Therapeutics Corp.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为41.72%、39.77%、30.19%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113230212953c9f36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113230212953c9f36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603572199","title":"Passage Bio, Inc.盘中异动 早盘股价大跌6.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603572199","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603572199?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:54","pubTimestamp":1768229664,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时54分，Passage Bio, Inc.股票出现波动，股价快速下跌6.30%。截至发稿，该股报18.60美元/股，成交量7315股，换手率0.23%，振幅4.79%。Passage Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Beam Therapeutics Inc.、Day One Biopharmaceuticals, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为554.06%、118.22%、59.28%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为31.29%、26.42%、25.56%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112225425a4bb1fec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112225425a4bb1fec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220799","title":"Passage Bio, Inc.盘中异动 早盘股价大跌7.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518220799?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613732,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Passage Bio, Inc.股票出现异动，股价急速跳水7.83%。截至发稿，该股报0.424美元/股，成交量2.1592万股，换手率0.03%，振幅0.20%。Passage Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2210.32%、428.24%、66.74%，振幅较大的相关个股有Akero Therapeutics, Inc.、Seer, Inc.、珐博进，振幅分别为100.05%、98.72%、98.49%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213533abf2fdd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213533abf2fdd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518447754","title":"Passage Bio, Inc.2024财年实现净利润-64.77百万美元，同比增加36.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518447754","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518447754?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449706,"startTime":"0","endTime":"0","summary":"3月9日，Passage Bio, Inc.公布财报，公告显示公司2024财年净利润为-64.77百万美元，同比增加36.50%；其中营业收入为0.00美元，每股基本收益为-1.07美元。从资产负债表来看，Passage Bio, Inc.总负债41.15百万美元，其中短期债务3.69百万美元，资产负债比为0.03，流动比率为4.08。机构评级：截至2025年3月9日，当前有5家机构对Passage Bio, Inc.目标价做出预测，其中目标均价为6.80美元，其中最低目标价为4.00美元，最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000329abef9957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000329abef9957&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517770169","title":"Passage Bio, Inc.盘中异动 大幅上涨5.66%报0.497美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517770169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517770169?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:15","pubTimestamp":1741274137,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时15分，Passage Bio, Inc.股票出现异动，股价大幅拉升5.66%。截至发稿，该股报0.497美元/股，成交量6849股，换手率0.01%，振幅2.13%。Passage Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。其相关个股中，Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Plus Therapeutics, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1518.72%、988.26%、77.08%，振幅较大的相关个股有Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Moolec Science Sa C/Wts ，振幅分别为56.82%、44.64%、44.44%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231537963c5641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231537963c5641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948525","title":"Passage Bio, Inc.盘中异动 快速上涨5.55%报0.449美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948525?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185081,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分，Passage Bio, Inc.股票出现波动，股价快速上涨5.55%。截至发稿，该股报0.449美元/股，成交量4373股，换手率0.01%，振幅0.00%。Passage Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Chimerix, Inc.、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为329.19%、252.19%、185.61%，振幅较大的相关个股有Aditxt, Inc.、Tango Therapeutics, Inc.、天境生物，振幅分别为23.90%、11.41%、11.10%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223121a260c71c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223121a260c71c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517825989","title":"Chardan Capital：维持Passage Bio(PASG.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至6.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517825989","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517825989?lang=zh_cn&edition=full","pubTime":"2025-03-05 06:01","pubTimestamp":1741125671,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Passage Bio(PASG.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至6.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05060148524532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516679367","title":"Passage Bio(PASG.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.20美元，前值为-0.30美元，预期值为-0.24美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679367","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516679367?lang=zh_cn&edition=full","pubTime":"2025-03-04 21:24","pubTimestamp":1741094692,"startTime":"0","endTime":"0","summary":"Passage Bio(PASG.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.20美元，前值为-0.30美元，预期值为-0.24美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04212448521455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516305746","title":"Passage Bio, Inc.盘中异动 快速跳水5.21%报0.491美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516305746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516305746?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:21","pubTimestamp":1741015296,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时21分，Passage Bio, Inc.股票出现异动，股价大幅跳水5.21%。截至发稿，该股报0.491美元/股，成交量6.6462万股，换手率0.11%，振幅5.39%。Passage Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aldeyra Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1775.26%、134.75%、116.67%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为177.97%、70.53%、48.34%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032321369637b980&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032321369637b980&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514537316","title":"Passage Bio, Inc.盘中异动 早盘股价大涨6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514537316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514537316?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:52","pubTimestamp":1740754358,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时52分，Passage Bio, Inc.股票出现波动，股价快速拉升6.49%。Passage Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为569.84%、361.16%、299.33%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Enveric Biosciences, Inc.，振幅分别为45.32%、31.14%、29.25%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225238a25806c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225238a25806c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514335998","title":"Passage Bio, Inc.盘中异动 股价大跌5.55%报0.482美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514335998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514335998?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:05","pubTimestamp":1740679549,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时05分，Passage Bio, Inc.股票出现异动，股价大幅下挫5.55%。截至发稿，该股报0.482美元/股，成交量6.4273万股，换手率0.10%，振幅8.43%。Passage Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.42%。其相关个股中，Pepgen Inc.、Cingulate Inc C/Wts 10/12/2026 、Heron Therapeutics, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1754.45%、308.88%、130.65%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Pepgen Inc.，振幅分别为86.14%、53.90%、52.29%。Passage Bio, Inc.公司简介：Passage Bio Inc是一家遗传药物公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280205499632da96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280205499632da96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PASG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.passagebio.com","stockEarnings":[{"period":"1week","weight":-0.2211},{"period":"1month","weight":-0.2171},{"period":"3month","weight":-0.4332},{"period":"6month","weight":-0.6082},{"period":"1year","weight":-0.3977},{"period":"ytd","weight":-0.6119}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Passage Bio, Inc.是一家位于特拉华州的公司，成立于2017年7月26日，是一家专注于开发罕见的单基因中枢神经系统疾病的转化疗法的基因药物公司。其愿景是成为领先的基因药物公司，并积极改变因为遭受这些疾病而受到生命威胁的患者生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.074245},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.017811},{"month":3,"riseRate":0,"avgChangeRate":-0.182325},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.090179},{"month":5,"riseRate":0.428571,"avgChangeRate":0.032304},{"month":6,"riseRate":0.285714,"avgChangeRate":0.000092},{"month":7,"riseRate":0.142857,"avgChangeRate":-0.135305},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.009674},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.13217},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.009774},{"month":11,"riseRate":0.5,"avgChangeRate":0.171558},{"month":12,"riseRate":0.666667,"avgChangeRate":0.114584}],"exchange":"NASDAQ","name":"Passage Bio, Inc.","nameEN":"Passage Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Passage Bio, Inc.(PASG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Passage Bio, Inc.(PASG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Passage Bio, Inc.,PASG,Passage Bio, Inc.股票,Passage Bio, Inc.股票老虎,Passage Bio, Inc.股票老虎国际,Passage Bio, Inc.行情,Passage Bio, Inc.股票行情,Passage Bio, Inc.股价,Passage Bio, Inc.股市,Passage Bio, Inc.股票价格,Passage Bio, Inc.股票交易,Passage Bio, Inc.股票购买,Passage Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Passage Bio, Inc.(PASG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Passage Bio, Inc.(PASG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}